Volume 10, Issue 2 (2024)
Pharm Biomed Res 2024, 10(2): 157-166 |
Back to browse issues page
1- Department of Pharmacology and Toxicology, College of Pharmacy, Al-Nahrain University, Baghdad, Iraq.
2- Department of Pharmacognosy, College of Pharmacy, Al-Nahrain University, Baghdad, Iraq.
2- Department of Pharmacognosy, College of Pharmacy, Al-Nahrain University, Baghdad, Iraq.
Abstract: (2089 Views)
Background: Psoriasis is a chronic, untreatable and disabling disease.
Objectives: In this research, we investigated the pharmacological properties of Euphorbia milii petroleum ether and ethyl acetate in a psoriasis mouse model.
Methods: Thirty-one albino mice were used in this study. They were divided into five groups: group I, healthy animals; group II, inducer group with imiquimod 12.5 mg (5% cream); and groups III, IV and V were imiquimod-induced and then treated with clobetasol 0.05% in group III, E. milii petroleum ether fraction in group IV and E. milii ethyl acetate fraction in group V. Immunohistochemistry for interleukin-17 (IL-17), vascular endothelial growth factor and transforming growth factor-beta, as well as histopathology were done on the mice skin.
Results: E. milii petroleum ether group showed a significant decrease in skin immunohistochemistry of IL-17, transforming growth factor-beta, and other histopathology parameters, while ethyl acetate fraction showed a significant reduction in vascular endothelial growth factor and other histopathology parameters
Conclusion: E. milii petroleum ether and ethyl acetate fractions may have a role in psoriasis treatment in a mice model.
Objectives: In this research, we investigated the pharmacological properties of Euphorbia milii petroleum ether and ethyl acetate in a psoriasis mouse model.
Methods: Thirty-one albino mice were used in this study. They were divided into five groups: group I, healthy animals; group II, inducer group with imiquimod 12.5 mg (5% cream); and groups III, IV and V were imiquimod-induced and then treated with clobetasol 0.05% in group III, E. milii petroleum ether fraction in group IV and E. milii ethyl acetate fraction in group V. Immunohistochemistry for interleukin-17 (IL-17), vascular endothelial growth factor and transforming growth factor-beta, as well as histopathology were done on the mice skin.
Results: E. milii petroleum ether group showed a significant decrease in skin immunohistochemistry of IL-17, transforming growth factor-beta, and other histopathology parameters, while ethyl acetate fraction showed a significant reduction in vascular endothelial growth factor and other histopathology parameters
Conclusion: E. milii petroleum ether and ethyl acetate fractions may have a role in psoriasis treatment in a mice model.
Keywords: Euphorbia milii, Interleukin-17 (IL-17), Imiquimod, Psoriasis, Vascular endothelial growth factor (VEGF)
Type of Study: Original Research |
Subject:
Pharmacology
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |